Issued 2026-08-13 at $5.33 · now $5.26 (2026-08-13, −1.3% since)
Based on its own history, a month from the 2026-08-13 close, ANNX has typically landed between $3.47 and $7.53 — a range of −34.9% to +41.3% from the issuance price $5.33.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,500 overlapping 1 month windows · 2020-07-24 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($5.33) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where ANNX has typically landed a month from the 2026-08-13 close of $5.33 — the range is history, not a prediction.
- now $5.26 (-1.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $5.36 (+0.5%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.43–$6.28
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.47–$7.53
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-04-26 | −60.7% | −60.7% | +19.1% |
| 2021-12-06 | −53.6% | −53.6% | +7.8% |
| 2023-05-16 | −53.5% | −65.2% | +5.5% |
| 3 best | |||
| 2023-12-04 | +102.1% | −0.8% | +104.2% |
| 2023-11-30 | +94.4% | −6.0% | +94.4% |
| 2023-12-01 | +92.7% | +0.0% | +106.8% |
1,500 overlapping windows · 2020-07-24 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 3 primary completion: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) (source, as of 2026-08-14)
- 2026-12-31 — Trial primary completion: Phase 3 primary completion: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.